BioInformant

Your Global Leader in Stem Cell Market Research

Home » iPS cells

Proteintech and HebeCell to Collaborate on Nanobody iPSC-derived NK Cells

By Leave a Comment

CHICAGO & NATICK, Massachusetts, Nov 11, 2020–Proteintech and HebeCell  announce their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR) technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK) cells, a promising cellular immunotherapy treatment for cancer and other diseases.

Proteintech’s recent acquisition of nanobody manufacturer, ChromoTek, has made them a leading player in the nanobody space. ChromoTek’s high-performing camelid single-chain recombinant reagents, also known as nanobodies, fuel breakthrough research discoveries.

HebeCell holds unique expertise and intellectual property in induced pluripotent stem cells (iPSC) and their lineage specific differentiation, especially toward natural killer (NK) cells. Although NK cells are best known for killing virally infected cells, they also play key roles in detecting and controlling early signs of cancer.

“Partnering with Proteintech will give both companies a competitive edge,” said Dr. Allen Feng, the Founder and Chief Scientific Officer of HebeCell, “Our combined expertise and technologies create a unique and special collaboration that will improve the treatment and care of cancer patients.”

Dr. Jason Li, CEO of Proteintech added, “I’ve known Dr. John Lu, Founder and CEO of HebeCell, for many years and I’m glad we have an opportunity to work together on this important project. With HebeCell’s proprietary NK cells and Proteintech’s nanobodies, the two companies can transform the future of cancer therapy. [Read more…]

Cynata to Launch World’s First Phase 3 Trial with an iPSC-Derived Cell Therapeutic

By

With an anticipated enrollment of 440 patients, it will be the world’s largest trial ever completed with an iPSC-derived cell therapeutic.

It’s official. Australian stem cell company Cynata Therapeutics is preparing to test its iPSC-derived cell therapeutic, CYP 004, in a Phase 3 clinical trial enrolling up to 440 patients.

Led by the University of Sydney and funded by the Australian Government National Health and Medical Research Council (NHMRC), the historic trial will assess whether Cynata’s cell therapeutic, CYP-004, has the capacity to improve patient outcomes in osteoarthritis (OA).

CYP-004 is an allogeneic, iPSC-derived mesenchymal stem cell (MSC) product derived using Cynata’s proprietary Cymerus™ technology. [Read more…]

Fate Therapeutics’ CRISPR-edited, iPSC-derived Cell Therapy Cleared for Clinical Investigation

By

Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for cancer and immune disorders, announced the U.S. FDA has cleared its Investigational New Drug (IND) application for FT538.

FT538 is the first CRISPR-edited, iPSC-derived cell therapy under development worldwide. [Read more…]

Induced Pluripotent Stem Cell (iPS Cell) Applications in 2020

By

Since the discovery of induced pluripotent stem cells (iPSCs) in 2006, a large and thriving research products market has emerged, largely because the cells are non-controversial and can be generated directly from adult cells. It is clear that iPSCs represent a lucrative market segment, because methods for commercializing this cell type are expanding every year and clinical studies investigating iPSCs are swelling in number. [Read more…]

BioInformant's World-Class Clients